Synthesis, Emission Characteristics, Cellular Studies, and Bioconjugation Properties of Luminescent Rhenium(I) Polypyridine Complexes with a Fluorous Pendant

Identification of novel potent and non-toxic anticancer, anti-angiogenic and antimetastatic rhenium complexes against colorectal carcinoma

Combination therapy targeting both tumor growth and vascularization is considered to be a cornerstone for colorectal carcinomas (CRC) treatment. However, the major obstacles of most clinical anticancer drugs are their weak selective activity towards cancer cells and inherent inner organs toxicity, accompanied with fast drug resistance development. In our effort to discover novel selective and non-toxic agents effective against CRC, we designed, synthesized and characterized a series of rhenium(I) tricarbonyl-based complexes with increased lipophilicity. Two of these novel compounds were discovered to possess remarkable anticancer, anti-angiogenic and antimetastatic activity in vivo (zebrafish-human HCT-116 xenograft model), being effective at very low doses (1-3 μM). At doses as high as 250 μM the complexes did not provoke toxicity issues encountered in clinical anticancer drugs (cardio-, hepato-, and myelotoxicity). In vivo assays showed that the two compounds exceed the anti-tumor and anti-angiogenic activity of clinical drugs cisplatin and sunitinib malate, and display a large therapeutic window.

Photophysical and biological investigation of phenol substituted rhenium tetrazolato complexes

The synthesis, structural and photophysical characterisation of four tricarbonyl rhenium(i) complexes bound to 1,10-phenanthroline and a tetrazolato ancillary ligand are reported. The complexes are differentiated by the nature (hydroxy or methoxy) and position (meta or para) of the substituent attached to the phenyl ring in conjugation to the tetrazole ring. The complexes exhibit phosphorescence emission from triplet charge transfer excited states, with the maxima around 600 nm, excited state lifetime decays in the 200-300 ns range, and quantum yield values of 4-6% in degassed acetonitrile solutions. The nature and position of the substituent does not significantly affect the photophysical properties, which remain unchanged even after deprotonation of the hydroxide group on the phenol ring. The interpretation of the photophysical data was further validated by resonance Raman spectroscopy and time-dependent density functional theory calculations. All the complexes are internalised within cells, albeit to variable degrees. As highlighted by a combination of flow cytometry and confocal microscopy, the species display diffuse cytoplasmic localisation except for the complex with the hydroxy functional group at the para position, which reveals lower accumulation in cells and more pronounced punctate staining. Overall, the complexes displayed low levels of cytotoxicity.

1IL and 3MLCT excited states modulated by H+: the structure and photophysical properties of [(2-bromo-5-(1H-pyrazol-1-yl)pyrazine)Re(CO)3Br]

The photophysical characterization of pyrazolyl–pyrazine Re(i) complex, shows a ¹IL and ³MLCT excited states, being just the ³MLCT able to react with trifluoroacetic acid to yield the protonated and long-lived ³ILH⁺ species. These findings make the compound a potential sensor for protons in solution in the presence of light.

Achieving yellow emission by varying the donor/acceptor units in rod-shaped fluorenyl-alkynyl based π-conjugated oligomers and their binuclear gold(i) alkynyl complexes

Fluorenyl-alkynyl based π-conjugated rod-shaped oligomers bearing different central aromatic moieties and functionalizable di-alkynyl termini, such as H-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-H (OH1), H-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Btz-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-H (OH2) and H-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Btd-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-H (OH3) where Fl = 9,9-dioctylfluorene, Btz = N-hexylbenzotriazole, and Btd = benzothiadiazole, were successfully synthesized by a Pd(0) catalyzed Stille coupling protocol. Electron withdrawing benzothiadiazole and benzotriazole as strong to moderate acceptors and fluorene as the donor have been incorporated to adjust the Donor-Acceptor (D-A) strength for fine-tuning the bandgap (E_g) as well as the emission wavelength. The corresponding digold(i) σ-complexes (PPh₃)Au-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Au(PPh₃) (OM1), (PPh₃)Au-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Btz-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Au(PPh₃) (OM2) and (PPh₃)Au-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Btd-[triple bond, length as m-dash]-Fl-[triple bond, length as m-dash]-Au(PPh₃) (OM3) have also been prepared by a reaction of Au(PPh₃)Cl and methanolic NaOMe in DCM with the corresponding alkynyl functionalized oligomers to take advantage of the heavy-atom effect on their emissive properties. The synthesized rod-shaped π-conjugated fluorene based oligomers and their binuclear Au(i) σ-complexes have been unambiguously characterized by various spectroscopic tools such as FTIR and multinuclear NMR as well as MALDI-TOF and CHN analyses. The absorption and emission spectral studies exhibited a progressive red shift with increasing the electron withdrawing character of the central aromatic unit. The rod-like oligomers having alkynyl termini and the corresponding digold(i) complexes are found to be blue, cyan and yellow emissive, demonstrating the fine-tuning of the emission wavelength. Most importantly, the fluorene based π-conjugated yellow light emitters OH3 and OM3 are successfully achieved by varying the donor/acceptor moiety to the fluorenyl-alkynyl backbone. The digold(i) diacetylide organometallic wires exhibit phosphorescence at 77 K in degassed CH₂Cl₂ due to the efficient intersystem crossing from the S₁ to the T₁ excited state as induced by heavy atoms.

The unsuspected influence of the pyridyl-triazole ligand isomerism upon the electronic properties of tricarbonyl rhenium complexes: an experimental and theoretical insight

How can the intimate nature of the triazole moiety govern the geometry and luminescence properties of a rhenium complex?

Exploring the cellular uptake and localisation of phosphorescent rhenium fac-tricarbonyl metallosurfactants as a function of lipophilicity

The cellular distribution of amphiphilic rhenium(i) complexes is tuned by the nature of the axial donor.

Recent development of luminescent rhenium(i) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents

This Perspective summarizes recent advances in the biological applications of luminescent rhenium(i) tricarbonyl polypyridine complexes.

Exploitation and application of a highly sensitive Ru(II) complex-based phosphorescent chemodosimeter for Hg2+ in aqueous solutions and living cells

A novel Ru(II) complex-based phosphorescent probe Rubpy-1 was designed and synthesized conveniently by incorporating of chemodosimeter into the luminophor, which exhibits good water solubility, longer excitation wavelength, and rapid turn-on phosphorescent response only toward Hg(2+) in aqueous system under physiological pH. The spectral response mechanism and Hg(2+)-promoted structure change of the chemodosimeter were analyzed in detail by theoretical calculations and electrospray ionization mass spectrometry. When time-resolved photoluminescence techniques were used, the Rubpy-1 could eliminate effectively the signal interference from the short-lived background fluorescence in complicated media, accompanied by the significant improvement of the signal-to-noise ratio and the accuracy of the detection. Furthermore, Rubpy-1 showed low cytotoxicity and excellent membrane permeability toward living cells, which was successfully applied to monitor intracellular Hg(2+) effectively by confocal luminescence imaging.

Underestimated potential of organometallic rhenium complexes as anticancer agents

In the recent years, organometallic compounds have become recognized as promising anti-cancer drug candidates. While radioactive (186/188)Re compounds are already used in clinics for cancer treatment, cold Re organometallic compounds have mostly been explored as luminescent probes for cell imaging and photosensitizers in photocatalysis. However, a growing number of studies have recently revealed the potential of Re organometallic complexes as anti-cancer agents. Several compounds have displayed cytotoxicity equaling or exceeding that of the well-established anti-cancer drug cisplatin. In this review, we present the currently known Re organometallic complexes that have shown anti-proliferative activity on cancer cell lines. A particular emphasis is placed on their cellular uptake and localization as well as their potential mechanism of action.

Towards cancer cell-specific phototoxic organometallic rhenium(I) complexes

Over the recent years, several Re(I) organometallic compounds have been shown to be toxic to various cancer cell lines. However, these compounds lacked sufficient selectivity towards cancer tissues to be used as novel chemotherapeutic agents. In this study, we probe the potential of two known N,N-bis(quinolinoyl) Re(I) tricarbonyl complex derivatives, namely Re(I) tricarbonyl [N,N-bis(quinolin-2-ylmethyl)amino]-4-butane-1-amine (Re-NH₂) and Re(I) tricarbonyl [N,N-bis(quinolin-2-ylmethyl)amino]-5-valeric acid (Re-COOH), as photodynamic therapy (PDT) photosensitizers. Re-NH₂ and Re-COOH proved to be excellent singlet oxygen generators in a lipophilic environment with quantum yields of about 75%. Furthermore, we envisaged to improve the selectivity of Re-COOH via conjugation to two types of peptides, namely a nuclear localization signal (NLS) and a derivative of the neuropeptide bombesin, to form Re-NLS and Re-Bombesin, respectively. Fluorescent microscopy on cervical cancer cells (HeLa) showed that the conjugation of Re-COOH to NLS significantly enhanced the compound's accumulation into the cell nucleus and more specifically into its nucleoli. Importantly, in view of PDT applications, the cytotoxicity of the Re complexes and their bioconjugates increased significantly upon light irradiation. In particular, Re-Bombesin was found to be at least 20-fold more toxic after light irradiation. DNA photo-cleavage studies demonstrated that all compounds damaged DNA via singlet oxygen and, to a minor extent, superoxide production.

pH luminescence switching, dihydrogen phosphate sensing, and cellular uptake of a heterobimetallic ruthenium(II)-rhenium(I) complex

A new heterobimetallic ruthenium(II)-rhenium(I) complex of [Ru(bpy)2(HL)Re(CO)3Cl](ClO4)2·6H2O (RuHLRe) {bpy = 2,2'-bipyridine and HL = 2-(4-(2,6-di(pyridin-2-yl)pyridin-4-yl)phenyl)-1H-imidazo[4,5-f][1,10]phenanthroline} was synthesised and characterised by elemental analysis, proton nuclear magnetic resonance spectroscopy, and mass spectrometry. The ground- and excited-state acid-base properties of RuHLRe were studied using UV-Vis absorption spectrophotometric and spectrofluorimetric titrations in a 100 : 1 (v/v) Britton-Robinson buffer-CH3CN solution combined with luminescence lifetime measurements. The complex exhibited two-step separate protonation-deprotonation processes in both the ground and excited states. The complex acted as pH-induced "off-on-off" luminescence switches (I(on)/I(off) = 31.0 and 14.6), with one of the switching actions being driven by pH variations over the physiological pH range (5.3-8.0). Importantly, cellular imaging and cytotoxicity experiments demonstrated that RuHLRe rapidly and selectively illuminated the membrane of HeLa cells over fixed cells and exhibited reduced cytotoxicity at the imaging concentration compared to the Re(I)-free parent Ru(II) complex. In addition, RuHLRe acted as an efficient "turn on" emission sensor for H2PO4(-) and "turn off" emission sensor for F(-) and OAc(-).

Enhanced Cytotoxicity through Conjugation of a "Clickable" Luminescent Re(I) Complex to a Cell-Penetrating Lipopeptide

Re(I) tricarbonyl polypyridine-based complexes are particularly attractive metal complexes in the field of inorganic chemical biology due to their luminescent properties, ease of conjugation to targeting biomolecules, and the possibility to prepare their "hot" (99m)Tc analogues for radioimaging. In this study, we prepared and characterized a novel, "clickable" complex, [Re(2,2'-bipyridine)(3-ethynylpyridine)(CO)3](BF4) ([Re(CO) 3 (bipy)(py-alkyne)](BF 4 )), exhibiting the characteristic luminescent properties and moderate cytotoxicity of this general class of compound. Using Cu(I)-catalyzed "click" chemistry, the complex was efficiently attached to a lipidated peptide known to increase cell permeability, namely, the myristoylated HIV-1 Tat peptide (myr-Tat), to give Re-myr-Tat. Fluorescence microscopy localization in human cervical cancer cells (HeLa) confirmed enhanced cellular uptake of Re-myr-Tat compared with [Re(CO) 3 (bipy)(py-alkyne)](BF 4 ), and cytotoxicity studies showed that this resulted in an increase in potency to a level comparable with cisplatin (13.0 ± 2.0 μM).

The path for metal complexes to a DNA target

The discovery of cisplatin as a therapeutic agent stimulated a new era in the application of transition metal complexes for therapeutic design. Here we describe recent results on a variety of transition metal complexes targeted to DNA to illustrate many of the issues involved in new therapeutic design. We describe first structural studies of complexes bound covalently and non-covalently to DNA to identify potential lesions within the cell. We then review the biological fates of these complexes, illustrating the key elements in obtaining potent activity, the importance of uptake and subcellular localization of the complexes, as well as the techniques used to delineate these characteristics. Genomic DNA provides a challenging but valuable target for new transition metal-based therapeutics.